The trading price of Immunome Inc. (NASDAQ:IMNM) closed higher on Tuesday, July 20, closing at $18.14, 9.01% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $17.90 and $24.96. In examining the 52-week price action we see that the stock hit a 52-week high of $63.78 and a 52-week low of $9.27. Over the past month, the stock has gained 9.81% in value.
Immunome Inc., whose market valuation is $214.05 million at the time of this writing, is expected to release its quarterly earnings report May 12, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.39 per share this quarter, however they have predicted annual earnings per share of -$1.66 for 2021 and -$1.86 for 2022. It means analysts are expecting annual earnings per share growth of 68.40% this year and -12.00% next year.
Analysts have forecast the company to bring in revenue of $3.8 million for the current quarter, with the likely lows of $3.8 million and highs of $3.8 million.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Immunome Inc. No upward and no downward comments were posted in the last 7 days.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned IMNM a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Immunome Inc. (IMNM) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that IMNM’s price is currently 8.03% off the SMA20 and 1.78% off the SMA50. The RSI metric on the 14-day chart is currently showing 55.47, and weekly volatility stands at 15.47%. When measured over the past 30 days, the indicator reaches 8.76%. Immunome Inc. (NASDAQ:IMNM)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 1.65. With analysts defining $54.00-$54.00 as the low and high price targets, we arrive at a consensus price target of $54.00 for the trailing 12-month period. The current price is about -197.68% off the estimated low and -197.68% off the forecast high, based on this estimate. Investors will be thrilled if IMNM’s share price rises to $54.00, which is the median consensus price. At that level, IMNM’s share price would be -197.68% below current price.
To see how Immunome Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: IMNM stock’s performance was 9.01% in the latest trading. Immunome Inc. has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has surged 1.52%, while the Dow Jones Industrial also saw a positive session, up 1.62% on the day.
An evaluation of the daily trading volume of Immunome Inc. (NASDAQ:IMNM) indicates that the 3-month average is 90.71K. However, this figure has increased over the past 10 days to an average of 31360.0.
Currently, records show that 10.64 million of the company’s shares remain outstanding. The insiders hold 10.90% of outstanding shares, whereas institutions hold 16.60%. The stats also highlight that short interest as of Jun 14, 2021, stood at 0.23 million shares, resulting in a short ratio of 2.36 at that time. From this, we can conclude that short interest is 1.93% of the company’s total outstanding shares. It is noteworthy that short shares in June were down slightly from the previous month’s figure, which was 0.23 million. However, since the stock’s price has seen 87.40% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.